NCT02644668.

Methods	Phase II, randomised, double‐blind, placebo‐controlled, 2 dose cohorts
Participants	72 participants, aged ≥ 12 years with genetically confirmed diagnosis of SMA and clinically SMA types II, III or IV
Interventions	Cohort 1: 36 participants with SMA type II, III or IV randomised 2:1 to CK‐2127107 150 mg or placebo. Cohort 2: 36 participants with SMA type II, III or IV randomised 2:1 to CK‐2127107 450 mg (or lower) or placebo. Both cohorts were also divided into 18 ambulatory versus 18 non‐ambulatory participants.
Outcomes	Change from baseline and slope of change from baseline in FVC, MIP, MEP, HHD, HFMSE, RULM, TUG, 6MWT, and safety and tolerability measurements
Notes	Study completed (May 2018), but no results are available yet.